A randomized phase II study (CHER-LOB) showed that the combination of lapatinib and trastuzumab is superior in achieving breast-conserving surgery or pCR in HER2 positive breast cancer patients, compared to either trastuzumab or lapatinib alone in combination with 12 weeks of paclitaxel followed by FEC chemotherapy. Here, ERBB2 is linked to breast cancer.